In a 2019 study, tesamorelin improved mitochondrial function in obese people with low growth hormone, as measured by better phosphocreatine recovery after exercise, and this improvement was linked to increased IGF-1 levels.
Scientific Claim
In a 12-month randomized, double-blind, placebo-controlled trial, tesamorelin improved mitochondrial oxidative capacity in obese adults with reduced growth hormone secretion, as measured by enhanced phosphocreatine recovery after exercise, with improvements strongly associated with increased IGF-I levels.
Original Statement
“In 2019, there was a study in the journal clinical endocrinology metabolism. This looked at tesarellin's effect on mitochondrial function in obese men and women with reduced growth hormone secretion. So they measured phosphocreatine recovery after exercise which is a wellestablished marker of mitochondrial oxidative capacity. After 12 months tesarellin really improved their recovery like significant and those improvements were strongly associated with increases in IGF-1 just insulin like growth factor one. So in other words, there was better mitochondrial efficiency, better energy handling, and better metabolic flexibility.”
Context Details
Domain
pharmacology
Population
human
Subject
tesamorelin
Action
improves
Target
mitochondrial oxidative capacity in obese adults with reduced growth hormone secretion
Intervention Details
Evidence from Studies
Supporting (3)
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
The study found that a drug called tesamorelin boosted a growth-related hormone (IGF-I) in obese people with low growth hormone, and those who got the drug recovered faster after exercise—meaning their muscle energy systems worked better, likely because their cell power plants (mitochondria) improved.
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
This study directly looks at how tesamorelin affects muscle energy recovery in obese adults with low growth hormone, which is exactly what the claim is about.
Supplemental Oxygen Improves In Vivo Mitochondrial Oxidative Phosphorylation Flux in Sedentary Obese Adults With Type 2 Diabetes
This study looks at how extra oxygen affects energy production in the bodies of obese adults with diabetes, which is somewhat similar to how tesamorelin might affect energy production in obese adults with low growth hormone.